About C4 Therapeutics, Inc.
https://www.c4therapeutics.comC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
CEO
Andrew J. Hirsch
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 30
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
LYNX1 CAPITAL MANAGEMENT LP
Shares:7.1M
Value:$16.54M
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:7.05M
Value:$16.44M
ORBIMED ADVISORS LLC
Shares:5.24M
Value:$12.2M
Summary
Showing Top 3 of 109
About C4 Therapeutics, Inc.
https://www.c4therapeutics.comC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $11.23M ▲ | $45.64M ▲ | $-32.17M ▼ | -286.43% ▲ | $-0.44 ▼ | $-31.71M ▼ |
| Q2-2025 | $6.46M ▼ | $34.96M ▼ | $-26.02M ▲ | -402.6% ▼ | $-0.37 | $-27.89M ▲ |
| Q1-2025 | $7.24M ▲ | $36.4M ▼ | $-26.32M ▲ | -363.66% ▲ | $-0.37 ▲ | $-28.71M ▲ |
| Q4-2024 | $5.18M ▼ | $41.12M ▼ | $-34.57M ▼ | -667.82% ▼ | $-0.49 ▼ | $-32.68M ▼ |
| Q3-2024 | $15.36M | $41.55M | $-24.67M | -160.57% | $-0.35 | $-22.61M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $191.88M ▼ | $265.49M ▼ | $111.08M ▼ | $154.41M ▼ |
| Q2-2025 | $214.55M ▼ | $296.53M ▼ | $122.46M ▼ | $174.06M ▼ |
| Q1-2025 | $215.09M ▼ | $319.52M ▼ | $124.38M ▼ | $195.14M ▼ |
| Q4-2024 | $244.9M ▼ | $349.6M ▼ | $133.62M ▲ | $215.99M ▼ |
| Q3-2024 | $255.64M | $376.06M | $133.4M | $242.66M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-32.17M ▼ | $-31.21M ▼ | $4.09M ▼ | $7.77M ▲ | $-19.35M ▼ | $-31.62M ▼ |
| Q2-2025 | $-26.02M ▲ | $-12.06M ▲ | $38.92M ▲ | $0 ▲ | $26.86M ▲ | $-12.24M ▲ |
| Q1-2025 | $-26.32M ▲ | $-33.28M ▼ | $29.13M ▲ | $-46K ▼ | $-4.21M ▼ | $-33.28M ▼ |
| Q4-2024 | $-34.57M ▼ | $-17.93M ▲ | $13.67M ▲ | $112K ▼ | $-4.15M ▲ | $-17.93M ▲ |
| Q3-2024 | $-24.67M | $-24.13M | $162K | $10.51M | $-13.46M | $-24.12M |
CEO
Andrew J. Hirsch
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 30
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
LYNX1 CAPITAL MANAGEMENT LP
Shares:7.1M
Value:$16.54M
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:7.05M
Value:$16.44M
ORBIMED ADVISORS LLC
Shares:5.24M
Value:$12.2M
Summary
Showing Top 3 of 109